# SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

> **NCT05141201** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1620 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05141201
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-21
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 1620 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141201, "SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05141201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*